![[Video] The Weekly Break Out Ep. 20: Pacific policy in Singapore and the UK’s new defense plan](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Break-Out-ep-20-thumb-Play-Button.jpg?#)
Theravance hands off the last of its Trelegy royalties to GSK for $225M
Theravance estimates that its lifetime earnings from GSK's inhaler Trelegy, born out of a 2002 collab, total $1.52 billion.
Theravance estimates that its lifetime earnings from GSK's inhaler Trelegy, born out of a 2002 collab, total $1.52 billion.
